A Phase 2 interventional study of vedolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-18.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 22nd largest by enrollment, is one of 2 that started in 2007, is one of 5 in phase 2, and was the 1st registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 30th largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2007, is one of 10 in phase 2, and was the 7th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to receive treatment with vedolizumab, and to determine the long term safety of vedolizumab in patients afflicted with these diseases.
This was a phase 2, multiple-dose, open-label study of vedolizumab administered intravenously (IV) every 8 weeks. The study population included treatment-naïve ulcerative colitis (UC) or Crohn's Disease (CD) participants, as well as 38 UC participants who had tolerated vedolizumab well during Study C13002 (NCT01177228).
In the original study protocol, all participants were randomized to receive vedolizumab at doses of either 6 mg/kg or 10 mg/kg. With the implementation of Amendment 1, the assigned doses of vedolizumab were decreased to 2.0 mg/kg and 6.0 mg/kg. To implement the dose changes, instead of randomizing all participants across both doses, those who rolled over from Study C13002 were reassigned to receive the 2.0 mg/kg dose and all participants who entered C13004 naïve to treatment were to receive the 6.0 mg/kg dose, starting on the next scheduled dosing day. Also, if participants assigned to the 2 mg/kg dose experienced flare, they were to receive the higher 6 mg/kg dose.
In the results analyses for this study, participants are grouped according to the lowest dose received, i.e., 2.0 mg/kg or 6.0 mg/kg vedolizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed and active ulcerative colitis (UC) or Crohn's Disease (CD)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
Drug: vedolizumab
Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
Drug: vedolizumab
Vedolizumab for intravenous (IV) infusion
Also known as: Entyvio, MLN0002, MLN02, LDP-02
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a patient administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. The investigator systematically collected information adequate to determine both the outcome and severity of the AE, and whether or not it was drug-related or met the criteria for classification as a serious adverse event (SAE). An SAE was defined as an AE that resulted in (or posed risk for) death, inpatient hospitalization (or prolonging hospitalization), or congenital, persistent or significant disability/incapacity. The intensity for each AE was defined according to the following criteria: Mild: Awareness of sign or symptom, but easily tolerated; Moderate: Discomfort enough to cause interference with normal daily activities; Severe: Inability to perform normal daily activities.
Time frame: From Day 1 to Day 637
Number of Participants With Clinically Significant Laboratory Findings
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are enzymes in the blood.
Time frame: through Day 637
Number of Participants With Signs and Symptoms of Progressive Multifocal Leukoencephalopathy (PML)
At every visit, before receiving study treatment participants were evaluated by clinic staff for signs of PML using a PML symptom checklist.
Time frame: through Day 637
Number of Participants With Human Anti-human Antibodies (HAHA)
Time frame: Samples collected prior to dosing on Days 1, 43, 155, 267, 379, 491, and 637.
Serum Concentration of Vedolizumab Before Dosing
Vedolizumab serum concentrations were measured from serum samples collected for pharmacokinetic (PK) analysis within 2 hours prior to dosing. The original protocol specified that PK parameters, including but not limited to minimum plasma concentration (Cmin), were to be estimated; however, due to intrapatient dose modification with Amendment 1, it was no longer feasible to perform a full PK parameter estimation. The summaries of pre-infusion data (i.e., trough levels) are presented at time points where at least 50% of participants had quantifiable vedolizumab concentrations, using a value of 0 for results below a measurable range. This provides information on the pharmacokinetic behavior of vedolizumab when administered as long-term therapy.
Time frame: Days 43, 99, 155 and 267, predose
Saturation of Receptors by Vedolizumab Before Dosing on Days 1, 43, 99, 155 and 267 by ACT-1 Assay
The target of vedolizumab is α4β7 integrin, a receptor found on inflammatory immune cells that guides these inflammatory cells to the gut and binds to the Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) on gut endothelial cells. The extent of the α4β7 receptor saturation by vedolizumab was assessed using the ACT-1 binding interference assay. ACT-1 is a mouse antibody similar to vedolizumab that also binds α4β7 integrin. The assay measures the percentage of cells bearing α4β7 that were not saturated with vedolizumab at the time of sampling.
Time frame: Days 43, 99, 155 and 267, predose
Saturation of Receptors by Vedolizumab Before Dosing Using the MAdCAM-1-Fc Assay
The target of vedolizumab is α4β7 integrin, a receptor found on inflammatory immune cells that guides these inflammatory cells to the gut and binds to the mucosal address in cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells. The extent of the α4β7 receptor saturation by vedolizumab was assessed using the MAdCAM-1-Fc binding interference assay at time points where at least 50% of participants in the analysis set had non-missing results. MAdCAM-1-Fc is a fusion of human MAdCAM-1 with parts of a mouse monoclonal antibody. The assay measures the percentage of cells bearing α4β7 that were not saturated with vedolizumab at the time of sampling.
Time frame: Days 43, 99, 155 and 267, predose
Participants took part in the study at 14 investigative sites in Canada and Russia, between 07 December 2007 and 31 March 2010.
| Milestone | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Started | 37 | 35 |
| Completed | 14 | 1 |
| Not completed | 23 | 34 |
| Withdrew: Adverse event | 0 | 7 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 11 |
| Withdrew: Rolled over to study c13008 (nct00790933 | 22 | 15 |
An adverse event (AE) is any untoward medical occurrence in a patient administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. The investigator systematically collected information adequate to determine both the outcome and severity of the AE, and whether or not it was drug-related or met the criteria for classification as a serious adverse event (SAE). An SAE was defined as an AE that resulted in (or posed risk for) death, inpatient hospitalization (or prolonging hospitalization), or congenital, persistent or significant disability/incapacity. The intensity for each AE was defined according to the following criteria: Mild: Awareness of sign or symptom, but easily tolerated; Moderate: Discomfort enough to cause interference with normal daily activities; Severe: Inability to perform normal daily activities.
| participants | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Any Adverse Event | 21 | 35 |
| Severe Adverse Event | 2 | 9 |
| Drug-related Adverse Event | 5 | 21 |
| Adverse Event Resulting in Discontinuation | 0 | 7 |
| Serious Adverse Event | 3 | 7 |
| Drug-related Serious Adverse Event | 1 | 4 |
| Serious Adverse Event Resulting in Discontinuation | 0 | 5 |
| On-study Deaths | 0 | 0 |
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are enzymes in the blood.
| participants | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Anemia | 3 | 0 |
| White Blood Cells Increased | 0 | 1 |
| White Blood Cells Decreased | 0 | 1 |
| C-reactive Protein Increased | 1 | 0 |
| Hypokalemia | 0 | 2 |
| Hypomagnesemia | 0 | 1 |
| Hepatic enzyme increased | 0 | 1 |
| ALT and AST Increased | 0 | 1 |
At every visit, before receiving study treatment participants were evaluated by clinic staff for signs of PML using a PML symptom checklist.
| participants | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Number of Participants With Signs and Symptoms of Progressive Multifocal Leukoencephalopathy (PML) | 0 | 0 |
| participants | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Number of Participants With Human Anti-human Antibodies (HAHA) | 2 | 1 |
Vedolizumab serum concentrations were measured from serum samples collected for pharmacokinetic (PK) analysis within 2 hours prior to dosing. The original protocol specified that PK parameters, including but not limited to minimum plasma concentration (Cmin), were to be estimated; however, due to intrapatient dose modification with Amendment 1, it was no longer feasible to perform a full PK parameter estimation. The summaries of pre-infusion data (i.e., trough levels) are presented at time points where at least 50% of participants had quantifiable vedolizumab concentrations, using a value of 0 for results below a measurable range. This provides information on the pharmacokinetic behavior of vedolizumab when administered as long-term therapy.
| μg/mL | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Day 43 (n=27, 19) | 25.2 ± 6.68 | 76.2 ± 36.9 |
| Day 99 (n=24, 18) | 11.2 ± 4.33 | 32.5 ± 20.5 |
| Day 155 (n=26, 17) | 8.40 ± 3.65 | 26.4 ± 17.7 |
| Day 267 (n=26, 12) | 7.40 ± 3.18 | 25.2 ± 11.7 |
The target of vedolizumab is α4β7 integrin, a receptor found on inflammatory immune cells that guides these inflammatory cells to the gut and binds to the Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) on gut endothelial cells. The extent of the α4β7 receptor saturation by vedolizumab was assessed using the ACT-1 binding interference assay. ACT-1 is a mouse antibody similar to vedolizumab that also binds α4β7 integrin. The assay measures the percentage of cells bearing α4β7 that were not saturated with vedolizumab at the time of sampling.
| % ACT1 binding | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Day 1 (0, 20) | NA ± NA | 14.6 ± 4.46 |
| Day 43 (26, 19) | 0.277 ± 0.216 | 0.311 ± 0.200 |
| Day 99 (n=26, 17) | 0.596 ± 0.690 | 0.288 ± 0.271 |
| Day 155 (n=26, 17) | 0.700 ± 1.50 | 1.09 ± 3.31 |
| Day 267 (n=25, 12) | 0.276 ± 0.247 | 0.767 ± 1.48 |
The target of vedolizumab is α4β7 integrin, a receptor found on inflammatory immune cells that guides these inflammatory cells to the gut and binds to the mucosal address in cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells. The extent of the α4β7 receptor saturation by vedolizumab was assessed using the MAdCAM-1-Fc binding interference assay at time points where at least 50% of participants in the analysis set had non-missing results. MAdCAM-1-Fc is a fusion of human MAdCAM-1 with parts of a mouse monoclonal antibody. The assay measures the percentage of cells bearing α4β7 that were not saturated with vedolizumab at the time of sampling.
| percent MADCAM binding | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Day 1 (n=0, 20) | NA ± NA | 18.5 ± 5.95 |
| Day 43 (n=26, 19) | 0.538 ± 0.512 | 0.705 ± 1.29 |
| Day 99 (n=26, 16) | 1.22 ± 1.20 | 0.838 ± 0.950 |
| Day 155 (n=26, 16) | 0.646 ± 0.673 | 0.369 ± 0.540 |
| Day 267 (n=25, 12) | 1.05 ± 1.38 | 0.975 ± 1.55 |
Collected over From Day 1 to Day 637. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vedolizumab 2 mg/kg | — | 3/37 (8.1%) | 12/37 (32.4%) |
| Vedolizumab 6 mg/kg | — | 7/35 (20%) | 27/35 (77.1%) |
| Event | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| Abdominal abscessInfections and infestations | 0/37 | 1/35 |
| Salmonella sepsisInfections and infestations | 0/37 | 1/35 |
| Viral infectionInfections and infestations | 0/37 | 1/35 |
| Small intestinal obstructionGastrointestinal disorders | 0/37 | 1/35 |
| Crohn's diseaseGastrointestinal disorders | 0/37 | 1/35 |
| Vision blurredEye disorders | 0/37 | 1/35 |
| Infusion-related reactionGeneral disorders | 0/37 | 1/35 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/37 | 1/35 |
| FuruncleInfections and infestations | 1/37 | 0/35 |
| Colitis ulcerativeGastrointestinal disorders | 1/37 | 0/35 |
| Event | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg |
|---|---|---|
| NasopharyngitisInfections and infestations | 5/37 | 7/35 |
| HeadacheNervous system disorders | 2/37 | 7/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/37 | 5/35 |
| InfluenzaInfections and infestations | 1/37 | 3/35 |
| Crohn's diseaseGastrointestinal disorders | 0/37 | 3/35 |
| NauseaGastrointestinal disorders | 0/37 | 3/35 |
| VomitingGastrointestinal disorders | 0/37 | 3/35 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/37 | 3/35 |
| Upper respiratory tract infectionInfections and infestations | 1/37 | 2/35 |
| Urinary tract infectionInfections and infestations | 0/37 | 2/35 |
The Safety Analysis Set defined as all enrolled participants who received at least 1 dose of study drug. Patients were analyzed based on the lowest dose they received. Baseline is the time closest to, but before, the start of study drug administration; for participants who rolled over from Study C13002 Baseline data are from the C13002 dataset.
| Age, Continuous(years) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| Mean | 42.0 ± 11.06 | 42.1 ± 15.79 | 42.1 ± 13.47 |
| Sex: Female, Male(Participants) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| Female | 21 | 22 | 43 |
| Male | 16 | 13 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 37 | 34 | 71 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| White | 37 | 34 | 71 |
| American Indian or Alaskan Native | 0 | 1 | 1 |
| Height(cm) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| Mean | 168.9 ± 8.83 | 168.4 ± 11.49 | 168.7 ± 10.14 |
| Weight(kg) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| Mean | 77.03 ± 17.620 | 70.81 ± 17.820 | 74.01 ± 17.868 |
| Body Mass Index (BMI)(kg/m^2) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| Mean | 27.04 ± 6.045 | 24.86 ± 5.286 | 25.98 ± 5.754 |
| Body Surface Area (BSA)(m^2) | Vedolizumab 2 mg/kg | Vedolizumab 6 mg/kg | Total |
|---|---|---|---|
| Mean | 1.89 ± 0.233 | 1.81 ± 0.270 | 1.85 ± 0.253 |
1 further baseline measures are reported on the registry.
The record gives a start of Dec 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab
Millennium Pharmaceuticals, Inc. →